Company Profile
Aurisco Pharmaceutical Limited, headquartered in Shanghai, China, is a privately held pharmaceutical company that was established in 2017. The company specializes in the research, development, and production of high-quality chemical products, with a particular focus on providing innovative and effective pharmaceutical solutions to benefit patients worldwide.
At the core of Aurisco Pharmaceutical Limited is a team of experienced chemists and researchers who are dedicated to advancing their research and product development efforts. The company's facilities are equipped with state-of-the-art equipment and technology, enabling the efficient and safe production of chemical products.
One of the company's notable areas of expertise lies in the development of cytotoxic drugs, which are instrumental in treating various types of cancer. Aurisco Pharmaceutical Limited has successfully developed and brought to market several cytotoxic drugs, such as imatinib mesylate and paclitaxel, and plans to expand its product portfolio in the future.
Beyond its involvement in cancer research, Aurisco Pharmaceutical Limited also maintains a strong presence in the field of Active Pharmaceutical Ingredients (APIs). The company's team of chemists possesses the capability to synthesize a wide range of APIs, including antibiotics, antihistamines, and anti-inflammatories.
Aurisco Pharmaceutical Limited is steadfast in its commitment to upholding the highest standards of quality and safety in its products and processes. The company is resolute in its dedication to providing customers with superior products and services, accompanied by ongoing research and development endeavors to enhance its products and processes further.
Aurisco Pharmaceutical Limited is a dynamic and forward-thinking pharmaceutical company headquartered in Shanghai, China. Its core emphasis on research, development, and the production of high-quality chemical products has earned the company a reputation as a leader in the pharmaceutical sector. With its unwavering commitment to quality and safety, Aurisco Pharmaceutical Limited is well-situated for continued growth and expansion in the future.
VIEW MORE VIEW LESS
Product List
| Product Name | Synonyms | CAS No. | Grate/Content | Operate |
|---|---|---|---|---|
Desogestrel |
18,19-Dinorpregn-4-en-20-yn-17-ol,13-ethyl-11-methylene-,(17α)-;(17α)-13-Ethyl-11-methylene-18,19-dinorpregn-4-en-20-yn-17-ol;17-Ethynyl-18-methyl-11-methyleneestr-4-en-17β-ol;Org 2969;13-Ethyl-11-methylene-18,19-dinor-17α-4-pregnen-20-yn-17-ol;Desogestrel;Cerazette;Dicromil;Cyclosa;Marvelon 150/320;(+)-Desogestrel;(+)-13β-Ethyl-17α-ethynyl-11-methylenegon-4-en-17β-ol |
54024-22-5 | Inquiry | |
Eplerenone |
Pregn-4-ene-7,21-dicarboxylic acid,9,11-epoxy-17-hydroxy-3-oxo-,γ-lactone,7-methyl ester,(7α,11α,17α)-;Pregn-4-ene-7,21-dicarboxylic acid,9,11-epoxy-17-hydroxy-3-oxo-,γ-lactone,methyl ester,(7α,11α,17α)-;Spiro[9,11-epoxy-9H-cyclopenta[a]phenanthrene-17(2H),2′(3′H)-furan],pregn-4-ene-7,21-dicarboxylic acid deriv.;CGP 30083;SC 66110;Eplerenone;SC 6110;Epoxymexrenone;Inspra;Selara;(+)-Eplerenone |
107724-20-9 | Inquiry | |
Etonogestrel |
18,19-Dinorpregn-4-en-20-yn-3-one,13-ethyl-17-hydroxy-11-methylene-,(17α)-;(17α)-13-Ethyl-17-hydroxy-11-methylene-18,19-dinorpregn-4-en-20-yn-3-one;17-Ethynyl-17β-hydroxy-18-methyl-11-methyleneestr-4-en-3-one;Org 3236;3-Keto-Org 2969;3-keto-Desogestrel;3-Ketodesogestrel;Etonogestrel;Implanon;3-Oxodesogestrel;Nexplanon;165050-21-5 |
54048-10-1 | Inquiry | |
Flumethasone |
Pregna-1,4-diene-3,20-dione,6,9-difluoro-11,17,21-trihydroxy-16-methyl-,(6α,11β,16α)-;Pregna-1,4-diene-3,20-dione,6α,9-difluoro-11β,17,21-trihydroxy-16α-methyl-;(6α,11β,16α)-6,9-Difluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione;U 10974;6α,9α-Difluoro-16α-methylprednisolone;6α,9-Difluoro-11β,17,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione;Flumethasone;6α-Fluorodexamethasone;6α,9α-Difluoro-16α-methyl-1,4-pregnadiene-11β,17α,21-triol-3,20-dione;Flumethason;Aniprime;Flucort;Methagon;Anaprime;Flucorticin;Fluvet;RS 2177;Cortexillar;Flumetasone;Vecort;6α-Fluorodexamethazone;Aniprome;NSC 5402;NSC 54702;Flutamethasone |
2135-17-3 | Inquiry |